Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. director K. Charles Janac reported an indirect sale of company stock executed under a pre-arranged trading plan. On December 4, 2025, an entity he manages, Bayview Legacy, LLC, sold 40,000 shares of Arteris common stock at a weighted average price of $16.4618 per share under a Rule 10b5-1 plan adopted on March 5, 2025. Following this transaction, Janac beneficially owned 9,599,071 shares of Arteris common stock indirectly through Bayview Legacy, LLC.
Arteris, Inc. (AIP) — Form 4 insider transaction: On 11/10/2025, a reporting person sold 50,000 shares of common stock at a weighted average price of $14.7366, coded as an open-market sale (S). The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025.
Following the transaction, the reporting person beneficially owned 9,639,071 shares, held indirectly through Bayview Legacy, LLC. The filer is identified as a Director. The price range for the sales was $14.34 to $14.95, with details available upon request.
Arteris, Inc. (AIP) disclosed an insider transaction: Chief Operating Officer Moll Laurent R. sold 32,775 shares of common stock on 11/05/2025 at a weighted average price of $15.4233. The shares were sold in multiple trades within a price range of $14.90–$15.90.
The transactions were executed under a Rule 10b5-1 trading plan adopted on March 12, 2025. After the sale, the reporting person beneficially owns 311,110 shares directly.
Arteris, Inc. (AIP) reported an insider transaction by its VP and General Counsel. On 11/03/2025, the officer exercised 5,000 options at $0.56 per share (code M) and sold 5,000 shares at a weighted average price of $13.162 (code S), with sale prices ranging from $12.98 to $13.59. The trades were made under a Rule 10b5‑1 trading plan adopted on June 5, 2025. Following the transactions, the officer reported 65,960 shares of common stock held directly and 80,000 derivative securities remaining. The option underlying the exercised shares expires on 10/23/2029, with vesting that began in 2020.
Arteris, Inc. (AIP) reported Q3 2025 results with total revenue of $17.4 million, up from $14.7 million a year ago as licensing, support and maintenance reached $15.9 million and variable royalties were $1.5 million. Gross profit was $15.6 million on a 90% gross margin profile. Operating expenses rose to $24.4 million, leading to a net loss of $9.0 million versus $7.7 million last year, or $0.21 per share.
The company ended September 30, 2025 with $17.4 million in cash and cash equivalents and $43.2 million in total investments. Deferred revenue was $85.9 million, and remaining performance obligations were $104.7 million. Annual Contract Value was $69.4 million, with ACV plus royalties at $74.9 million as of September 30, 2025. Net cash provided by operating activities for the nine months was $3.6 million.
Arteris reported 23 Confirmed Design Starts in the quarter. As of October 28, 2025, there were 43,683,773 common shares outstanding. In litigation, on September 4, 2024, a Texas federal court dismissed all claims against the company without prejudice in the NST matter.
Arteris, Inc. furnished a Form 8‑K stating it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company noted that the information in Items 2.02 and 9.01, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act. Arteris’ common stock trades on Nasdaq under the symbol AIP.
Arteris, Inc. reporting person Janac K. Charles disclosed insider sales executed under a 10b5-1 trading plan adopted on 03/05/2025. The filing shows a weighted-average sale of $13.0742 for 50,000 shares sold on 10/08/2025. After the reported transactions, the reporting person is listed as having 9,689,071 shares beneficially owned indirectly through Bayview Legacy, LLC, and additional holdings are noted through the Charles and Lydia Janac Trust. The report was signed by an attorney-in-fact on 10/10/2025. The sale is identified as made pursuant to a pre-established trading plan and the filing discloses the range of execution prices between $13.00 and $13.20.
Arteris, Inc. (AIP) reporting person Bayview Legacy, LLC (managed by K. Charles Janac) sold 50,000 shares of common stock on 10/08/2025 under a pre-existing 10b5-1 trading plan. The weighted average sale price was $13.0742 (individual trades ranged from $13.00 to $13.20). After the sale, Bayview Legacy, LLC is reported to beneficially own 9,689,071 shares indirectly through the manager relationship. The filing notes that Janac separately filed an individual Form 4 to report the same transaction and confirms he is deemed to have voting and dispositive power over the shares held by Bayview Legacy, LLC.
Insider sale under 10b5-1 plan. The filing shows that Nicholas B. Hawkins, Vice President and Chief Financial Officer of Arteris, Inc. (AIP), sold 6,421 shares of common stock on 10/07/2025 at a weighted average price of $13.2073 per share. The report states the sales were executed under a 10b5-1 trading plan adopted on 06/04/2025. After the transactions, Hawkins beneficially owned 93,590 shares. The filer notes the sale prices ranged from $12.85 to $14.11 and offers to disclose per‑price quantities on request.
Arteris, Inc. director, president and CEO Janac K. Charles reported sales under a pre-established 10b5-1 plan. On 10/06/2025 the reporting person sold 5,755 shares at a listed price of $14 and sold an additional 100,000 shares at a weighted average price of $13.1045 (individual trades ranged from $12.50 to $13.85). After these transactions, direct beneficial ownership is reported as 161,759 shares and indirect ownership through entities is 9,739,071 shares. The filing notes the sales were executed pursuant to a trading plan adopted on 03/05/2025.